SCHEMBL13612282

SCHEMBL13612282

N#CCCC1CCN(c2cc(N3CCN(c4cccc(C(F)(F)F)c4)CC3)c(F)cc2/C=N/NC(N)=S)CC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.43
MAPT P10636 2/20 0.43
HTT P42858 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
ALOX12 P18054 1/20 0.42
RECQL P46063 1/20 0.40
MEN1 O00255 1/20 0.39
POLB P06746 1/20 0.39
XBP1 P17861 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C19 P33261 1/20 0.38
SERPINE1 P05121 1/20 0.37
PHGDH O43175 5/20 0.37
CHRM4 P08173 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4323919 0.89 LMNA (0.41) LMNAMAPTHTTSMN1; SMN2ALOX12
SCHEMBL4323917 0.89 LMNA (0.41) LMNAMAPTHTTSMN1; SMN2ALOX12
SCHEMBL4331981 0.85 LMNA (0.48) LMNAMAPTHTTSMN1; SMN2ALOX12
SCHEMBL4331984 0.85 LMNA (0.48) LMNAMAPTHTTSMN1; SMN2ALOX12
SCHEMBL4334844 0.84 LMNA (0.49) LMNAMAPTHTTSMN1; SMN2ALOX12
SCHEMBL4334847 0.84 LMNA (0.49) LMNAMAPTHTTSMN1; SMN2ALOX12
SCHEMBL4336323 0.84 LMNA (0.49) LMNAMAPTHTTSMN1; SMN2ALOX12
SCHEMBL4336320 0.84 LMNA (0.49) LMNAMAPTHTTSMN1; SMN2ALOX12
SCHEMBL4334437 0.84 LMNA (0.46) LMNAMAPTHTTSMN1; SMN2ALOX12
SCHEMBL4334434 0.84 LMNA (0.46) LMNAMAPTHTTSMN1; SMN2ALOX12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090285849-A1 Thiosemicarbazones as anti-virals and immunopotentiators MAVS, IRF3, HAVCR2 LMNA 4884/4885MAPT 3619/4885HTT 2994/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.